Richard N. Kender
Interim CEO & Executive ChairMr. Richard N. Kender, also known as Rich, BS, MBA, is Interim CEO & Executive Chair of Seres Therapeutics, Inc. from March 2, 2026 and has been its Director since October 2014 and was its Independent Director since October 2014 until March 2026. He was Director of Bicycle Therapeutics plc since July 18, 2019. He has been an Independent Director of Omega Therapeutics. He was Independent Director of Longeveron Inc. since May 10, 2024 until March 2026. He was Non-Executive Director of ReViral Ltd since November 2019 until June 2022. He was Senior Vice President of Business Development and Corporate Licensing at Merck & Co., Inc. from 2000 to 2013. During his career at Merck, he was actively involved in more than 100 transactions, including a number that greatly influenced the course of the company. He also held positions with Merck in corporate finance, as well as in financial support of the domestic and international commercial and manufacturing divisions. He is a consultant to biotechnology companies in the areas of partnerships and licensing and mergers and acquisitions. From October 1978 to September 2013, Mr. Kender held positions in a variety of corporate areas at Merck & Co., Inc. and was its Senior Vice President of Business Development and Corporate Licensing. Mr. Kender has experience in the pharmaceutical industry and has extensive business experience. His professional career at Merck includes various corporate areas and was actively involved in more than 100 transactions of different sizes and transaction types. Mr. Kender served as Senior Vice President of Merck & Co., Inc. since February 2008 and served as Vice President of Business Development and Corporate Licensing from 2000 to February 2008. From 1996 to 2000, he served as Vice President of Corporate Development of Merck & Co. He had been an Independent Director of Poxel SA since March 12, 2015 until July 31, 2025. Mr. Kender had been a Director at Abide Therapeutics, Inc since December 2015 and May 2019. He served as an Independent Director of INC Research Holdings, Inc. since December 8, 2014 until August 2017. He served as a Director of Foxhollow Technologies, Inc. since November 8, 2006. He served as a Director of BioNJ Inc. Mr. Kender was a Member of Merck's Finance Senior Leadership Team. He served as a Director of ev3 Inc. from October 2007 to July 25, 2008. Mr. Kender holds a Bachelor of Science in Accounting from Villanova University and an MBA from Fairleigh Dickinson University.
Positions
- Company NameSeres Therapeutics, Inc.Stock CodeMCRBPositionInterim CEO & Executive ChairColleagues
- MRMatthew R. HennPresident & Chief Scientific Officer
- TJThomas J. DesRosierExecutive VP, Chief Legal Officer & Secretary
- KBKelly BradyExecutive VP & COO
- CMChris McChalicherExecutive VP & CTO
- KCKurt C. GravesIndependent Director
- WHWillard H. DereIndependent Director
- SAStephen A. BerensonIndependent Director
- EDEric D. ShaffDirector
